Montreal – October 7, 2021 – CQDM, the Canadian Cancer Society (CCS), the Cole Foundation (CF) and Oncopole – Pôle cancer du FRQS launch a first call for proposals to support collaborative R&D projects focusing on pediatric and young adult cancers, in particular leukemia and lymphoma. This new research funding, worth up to $5M, builds…
CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies, to support the development of innovative therapies for acute liver failure Montréal – Québec – July 7 – CQDM is proud to announce an investment of $260,100 in Morphocell Technologies, a Montréal- based early-stage regenerative medicine company focused on the development of stem cell-derived engineered liver…
Montreal – June 30th 2021 – CQDM is proud to invest in Giiant Pharma’s seed financing round, joining co-leads Amplitude Ventures and Genesys Capital, along with Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, AQC Capital, Anges Québec, and other angel investor. This financing will enable Giiant Pharma to become a leader in…
CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University to develop new treatments for Amyotrophic Lateral Sclerosis (ALS) MONTREAL, June 21, 2021 – On this Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, CQDM is proud to announce a new $1.7M international collaboration between McGill University, Raya Therapeutic (Montreal – Quebec)…
CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet to develop new chemistry to facilitate drug development and manufacturing MONTREAL, June 2nd, 2021 – CQDM is proud to announce a partnership with 3 major pharmaceutical companies, Amgen Canada, Merck Canada, Servier Canada and the Canadian Glycomics Network (GlycoNet) as part…
Montréal, May 11, 2021 – The Institute for Data Valorization (IVADO) is pleased to announce the signing of network partnerships with the Consortium de recherche biopharmaceutique (CQDM, biopharmaceutical research consortium), the Industrial Consortium for Research and Innovation in Medical Technologies (MEDTEQ+) and Montréal InVivo, the life sciences and health technologies (LSHT) cluster of Greater Montréal.…
MONTREAL, April 28, 2021 — The chairman of the Board of Directors of CQDM, Richard Fajzel, and Diane Gosselin, President and CEO, are very pleased to announce the appointment of Brian Underdown as the new chairman on its Scientific Advisory Board (SAB). Also, David Bouffard, Christine Brideau and Benjamin Haibe-Kains are joining this strategic committee,…
Montréal – Québec – March 15, 2021 – 48Hour Discovery(48HD) and CQDM are proud to announced that the company has been awarded $800,000 for peptide drug discovery using its patented drug discovery platform. The two-year project is funded through the CQDM Quantum Leap program, which supports exploration of innovative technologies, tools, and platforms that accelerate…
Pr. David Y. Thomas / Pr. John Hanrahan Montreal (Quebec), February 25, 2021—CQDM is proud to announce the launch of a $2,025,077 international collaborative project to support the preclinical stages of new drug candidates to treat an orphan lung disease. Led by Professor David Y. Thomas of McGill University, this multi-partner project focuses on the development…
On January 20th, CQDM’s President and CEO, Diane Gosselin, participated in the pre-budget consultations held by the team of Finance Minister Eric Girard. This exercise allowed us to share our thoughts and submit our proposals for the next Quebec government budget. To view the brief: click here. In the wake of the pandemic, we have…